Bicara Therapeutics Inc. (BCAX) Current Ratio
- Current ratio · latest quarter: Value 11.59×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 11.59× | Current assets / current liabilities. $503.82M ÷ $43.48M ≈ 11.59× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 503.82M USD | Assets, Current |
| Current obligations | 43.48M USD | Liabilities, Current |
| Cash and equivalents | 96.60M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 400.66M USD | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | (m) | |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $503.82M | $43.48M | $96.60M | $400.66M | (m) | (m) | (m) | (m) | 11.59× |
| 2026-03-31 | $544.91M | $39.34M | $323.46M | $216.29M | (m) | (m) | (m) | (m) | 13.85× |
| 2025-12-31 | $422.05M | $28.95M | $96.69M | $318.12M | (m) | (m) | (m) | (m) | 14.58× |
| 2025-09-30 | $297.37M | $21.03M | $171.67M | (m) | (m) | (m) | (m) | (m) | 14.14× |
| 2025-06-30 | $444.39M | $17.23M | $436.61M | (m) | (m) | (m) | (m) | (m) | 25.80× |
| 2025-03-31 | $470.75M | $19.12M | $462.06M | (m) | (m) | (m) | (m) | (m) | 24.62× |
| 2024-12-31 | $502.53M | $17.99M | $489.71M | (m) | (m) | (m) | (m) | (m) | 27.93× |
| 2024-09-30 | $521.51M | $14.48M | $520.76M | (m) | (m) | (m) | (m) | (m) | 36.01× |
| 2023-12-31 | $231.07M | $15.09M | $230.44M | (m) | (m) | (m) | (m) | (m) | 15.32× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B |